BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Former Hansen Medical Executives Charged With Fraud


10/7/2011 7:04:54 AM

By Eli Segall, Reporter - Silicon Valley / San Jose Business Journal

Government regulators on Thursday filed fraud charges against two former sales executives at Mountain View medical equipment company Hansen Medical Inc.

Christopher Sells, former vice president of commercial operations at Hansen, and Timothy Murawski, a former vice president of sales, allegedly participated in “multiple improper sales transactions” to inflate the company’s reported revenues, said the U.S. Securities and Exchange Commission.

According to the SEC, the two men engaged in the scheme in 2008 and 2009 as Hansen (NASDAQ:HNSN) “underwent efforts to raise additional capital from investors.”

The agency’s complaint said that Sells, a Dallas resident, and Murawski, who lives in Lake Zurich, Ill., “schemed” to have Hansen personnel temporarily install the company’s robotic catheter system at a customer site before the customer was ready for it, so that Hansen could record the sale.

According to the SEC, Hansen personnel would then “immediately dismantle the equipment and put it in storage until months later, when they would return to reinstall the equipment.”

The SEC also alleged that, in a sales transaction in late December 2008, Sells and Murawski told Hansen personnel “to forge a customer signature on certain required documents to allow the company to record the revenue that quarter.”

According to the SEC, Sells and Murawski’s schemes were intended “to fool Hansen Medical’s finance personnel and auditors” into believing the sales were completed, and revenue could be recorded.

Peter Mariani, the chief financial officer of Hansen, did not immediately return a call seeking comment on the charges.

The SEC also said Thursday that, in a separate proceeding, the agency settled charges against Hansen for providing misleading financial information to public investors.

Hansen announced Thursday that its settlement with SEC “fully resolves” the agency’s investigation of issues related to the restatement of financial statements that were first reported in October 2009.

In agreeing to the settlement, Hansen neither admitted nor denied the SEC’s findings.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES